BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2911781)

  • 1. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
    Alberts AS; Falkson G
    S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A prolonged-action somatostatin analog and carcinoid syndrome].
    Chayvialle JA
    Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of malignant carcinoid syndrome with a long-acting somatostatin analogue.
    Altman AR; Tschen JA; Rice L
    Arch Dermatol; 1989 Mar; 125(3):394-6. PubMed ID: 2923448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
    Janson ET; Oberg K
    Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of carcinoid syndrome with a somatostatin analogue].
    Döbrönte Z; Stöckert A; Végh G; Varga L
    Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
    Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
    N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide treatment of carcinoid hypertensive crisis.
    Warner RR; Mani S; Profeta J; Grunstein E
    Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin, anaesthesia, and the carcinoid syndrome. Peri-operative administration of a somatostatin analogue to suppress carcinoid tumour activity.
    Roy RC; Carter RF; Wright PD
    Anaesthesia; 1987 Jun; 42(6):627-32. PubMed ID: 2887127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Carcinoid tumor--diagnostic and therapeutic problems].
    Batowski S; Bielewicz A
    Pol Tyg Lek; 1994 Jun 6-13; 49(23-24):536-7. PubMed ID: 7675710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.
    Deguchi H; Deguchi K; Tsukada T; Murashima S; Iwasaki E; Tsuda M; Kobayashi T; Shirakawa S
    Intern Med; 1994 Feb; 33(2):100-2. PubMed ID: 7517229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic principles in the management of metastasising carcinoid tumors: drugs for symptomatic treatment.
    Gregor M
    Digestion; 1994; 55 Suppl 3():60-3. PubMed ID: 7698539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A favorable response to the somatostatin analog SMS 201-995 in a patient with the carcinoid syndrome].
    Del Val A; Ponce J; Talens A; Martí-Bonmati L; Garrigues V; Berenguer J
    Rev Esp Enferm Dig; 1991 Mar; 79(3):215-7. PubMed ID: 2043408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Migratory thrombophlebitis during sandostatin (SMS 201-995, Sandoz) therapy for malignant carcinoid syndrome.
    Nathanson L; Sochet A; Williams ME
    Invest New Drugs; 1989 Jul; 7(2-3):285-7. PubMed ID: 2793386
    [No Abstract]   [Full Text] [Related]  

  • 14. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
    Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
    J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of a patient with carcinoid syndrome with SMS-201-995 (octreotide) for 32 months].
    Marcos Sánchez F; Juárez Ucelay F; Plaza Díaz R; García Camba L; Durán Pérez-Navarro A
    An Med Interna; 1993 Jun; 10(6):309. PubMed ID: 8334213
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful symptomatic treatment of malignant carcinoid syndrome with the somatostatin analogue SMS 201-995.
    van Houten AA; Nortier JW; Vendrik CP
    Neth J Med; 1988 Apr; 32(3-4):194-8. PubMed ID: 2896307
    [No Abstract]   [Full Text] [Related]  

  • 17. Somatostatin and a long-acting analogue, octreotide acetate. Relevance to dermatology.
    Camisa C
    Arch Dermatol; 1989 Mar; 125(3):407-12. PubMed ID: 2564269
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b].
    Linkesch M; Kuzmits R; Geyer G
    Wien Klin Wochenschr; 1989 Jun; 101(13):455-7. PubMed ID: 2763566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of the carcinoid syndrome with somatostatin, salmon calcitonin, or octreotide.
    Antonelli A; Gambuzza C; Bertoni F; Baschieri L
    Clin Ther; 1992; 14(2):178-84. PubMed ID: 1377097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
    Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
    Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.